Clinical Trials

Breast Neoplasms, Neoplasm, Residual

NCT04360941 2026-04-06

PAveMenT

Phase 1 Recruiting

45 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07493291 2026-03-30

PALLAS-IRAQ

Active not recruiting

100 enrolled

Breast Neoplasms

NCT07487129 2026-03-23

Clinical and P

Phase 4 Completed

206 enrolled

Breast Neoplasms

NCT03573648 2026-03-19

ImmunoADAPT

33 enrolled

Breast Neoplasms

NCT06377852 2026-03-18

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Phase 3 Recruiting

500 enrolled

Breast Neoplasms

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

47 enrolled 17 charts

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT02947685 2026-02-12

PATINA

518 enrolled 15 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT02513394 2026-02-10

PALLAS

5,796 enrolled 14 charts

Breast Neoplasms

NCT02668666 2026-01-20

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

49 enrolled 14 charts

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT03685331 2026-01-09

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

9 enrolled

Breast Neoplasms

NCT02942355 2026-01-07

Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

40 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07299890 2025-12-23

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

90 enrolled

Breast Neoplasms

NCT05069038 2025-12-22

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

51 enrolled

Breast Neoplasms

NCT02760030 2025-12-19

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

14 enrolled

Breast Neoplasms

NCT04563507 2025-12-15

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Phase 2 Recruiting

102 enrolled

Breast Neoplasms

NCT02738866 2025-12-10

Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

60 enrolled

Breast Neoplasms

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

84 enrolled 17 charts

Breast Neoplasms

NCT03079011 2025-11-18

PADA-1

Phase 3 Completed

1,017 enrolled

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Phase 2 Recruiting

174 enrolled

Breast Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

220 enrolled 11 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

77 enrolled

Breast Neoplasms

NCT03535506 2025-09-26

WI223281

Phase 2 Terminated

17 enrolled 9 charts

Phase 1/2 Active not recruiting

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

44 enrolled

Phase 1/2 Active not recruiting

Breast Diseases, Breast Neoplasms

NCT02605486 2025-07-03

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

46 enrolled

BreastClassical hematology

Breast Neoplasms

NCT07008508 2025-06-06

BRAVE-Cyclin

Active not recruiting

300 enrolled

Breast Neoplasms, Cardiovascular Diseases, Venous Thromboembolism

NCT02764541 2025-05-07

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

195 enrolled 26 charts

Breast Neoplasms, Carcinoma, Lobular

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

162 enrolled 12 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT05207709 2025-04-29

HARMONIA

456 enrolled

Phase NA Not yet recruiting

Breast Neoplasms

NCT06810492 2025-03-17

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

40 enrolled

Breast Neoplasms

NCT03691493 2025-02-17

ASPIRE

36 enrolled 17 charts

Breast Neoplasms

NCT03854903 2025-02-06

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

19 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06805812 2025-02-03

PALMARES-2

Recruiting

3,500 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast Neoplasms

NCT06525675 2024-12-13

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

Completed

419 enrolled

Breast Neoplasms

NCT02491983 2024-12-09

PARSIFAL

486 enrolled 15 charts

Breast Neoplasms

NCT03238196 2024-11-14

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

35 enrolled 19 charts

Breast Neoplasms

NCT03355157 2024-10-01

PADMA

Phase 4 Completed

130 enrolled

Breast Neoplasms, Patient Acceptance of Health Care

NCT02389842 2024-09-26

PIPA

79 enrolled

Breast Neoplasms

NCT02028507 2024-09-25

PEARL

Phase 3 Completed

693 enrolled 40 charts

Phase EARLY_PHASE1 Completed

Breast Neoplasms

NCT02913430 2024-09-23

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

7 enrolled 13 charts

Breast Neoplasms

NCT06607601 2024-09-23

CARE Initiative: Real-world Emulation of the PALOMA-2 Trial

Completed

724 enrolled

Phase NA Active not recruiting

Breast Neoplasms, Neoplasms

NCT03870919 2024-09-19

PALATINE

200 enrolled

Breast Neoplasms

NCT03530696 2024-08-13

T-DM1

55 enrolled 19 charts

Breast Neoplasms

NCT02448420 2024-04-18

PATRICIA II

73 enrolled

Breast Neoplasms

NCT06338644 2024-03-29

Palbociclib

Not yet recruiting

100 enrolled

Breast Neoplasms

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

55 enrolled 15 charts